Core Viewpoint - Xiansheng Pharmaceutical (02096) has seen a stock price increase of over 4%, currently trading at HKD 13.42 with a transaction volume of HKD 89.99 million, following the announcement of a clinical trial for its innovative anti-tumor drug SIM0505 [1] Group 1: Clinical Trial Announcement - Xiansheng Pharmaceutical's subsidiary, Xiansheng Zaiming, has completed the first dosing of SIM0505 in a Phase I clinical trial for advanced solid tumor patients in the U.S. [1] - The trial aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SIM0505 [1] Group 2: Drug Details - SIM0505 is a novel ADC targeting CDH6 (calcium adhesion protein-6 or K-cadherin), with a higher affinity for tumor antigens compared to similar candidates [1] - The drug utilizes Xiansheng Zaiming's proprietary TOPO I inhibitor as an effective payload, providing strong anti-tumor activity and a high systemic clearance rate, thus expanding the therapeutic window [1] Group 3: Global Expansion - The Phase I dose-escalation study initiated in China has been expanded to the U.S. by NextCure, which has begun enrolling U.S. patients in the mid-dose group [1] - NextCure has obtained exclusive global licensing rights for SIM0505 outside of Greater China [1]
先声药业涨超4% 先声再明新型ADC候选药物SIM0505完成Ⅰ期临床美国首例患者入组